healthcareЗдравоохранение. HealthcareHealthcare1027-7218Republican Scientific and Practical Center for Medical Technologies, Informatization, Management and Health Economicshealthcare-33Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEЛечение тоцилизумабом кортикостероид-резистентных форм аутоиммунной орбитопатии при болезни ГрейвсаTreatment with tocilizumab for corticosteroid-resistant forms of autoimmune orbitopathy in Graves' diseaseМохортТ. В.MokhortT. V.

Мохорт Tатьяна Вячеславовна — д. м. н., профессор

Пр. Дзержинского, 83, 220083, Минск

Cл. тел. +375 17 282-04-87

ПоловинкинаК. А.PolovinkinaK. A.

Минск

ШишкоО. Н.ShishkoV. N.

Минск

МохортЕ. Г.MokhortA. G.

Минск

ЕреняЕ. В.YurenyaA. V.

Минск

ЛихорадН. М.LikhoradN. M.

Минск

ДягилеваО. К.DyagilevaA. K.

Минск

Белорусский государственный медицинский университетBelarusМинский городской клинический эндокринологический центрBelarus31-я городская клиническая больницаBelarus202422092025044652Copyright © Мохорт Т.В., Половинкина К.А., Шишко О.Н., Мохорт Е.Г., Ереня Е.В., Лихорад Н.М., Дягилева О.К., 20252025Мохорт Т.В., Половинкина К.А., Шишко О.Н., Мохорт Е.Г., Ереня Е.В., Лихорад Н.М., Дягилева О.К.Mokhort T.V., Polovinkina K.A., Shishko V.N., Mokhort A.G., Yurenya A.V., Likhorad N.M., Dyagileva A.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://healthcare.ejournal.by/jour/article/view/33

B статье описан опыт применения тоцилизумаба у трех пациенток с аутоиммунной орбитопатией тяжелой степени, которые не имели ответа на лечение внутривенной пульс-терапией кортикостероидами. Aльтернативой для этих пациенток было только хирургическое вмешательство. Целью статьи являлась оценка эффективности и безопасности лечения тоцилизумабом данной патологии.

The article describes the experience of tocilizumab using in three patients with severe autoimmune orbitopathy who did not respond to treatment with pulse corticosteroid therapy. The only alternative for these patients was surgery. Our goal was to evaluate the effectiveness and safety of treatment with tocilizumab for this pathology.

аутоиммунная орбитопатияболезнь Γрейвсатоцилизумабкортикостероид-резистентные формыautoimmune orbitopathyGraves´ diseasetocilizumabcorticosteroid-resistant formsReferencesBartalena L., Baldeschi L., Boboridis K. et al. European Group on Graves´ Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves´ Orbitopathy Guidelines for the Management of Graves´ Orbitopathy. Eur. Thyroid J. 2016; 5 (1): 9—26.Bartalena L., Baldeschi L., Boboridis K. et al. European Group on Graves´ Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves´ Orbitopathy Guidelines for the Management of Graves´ Orbitopathy. Eur. Thyroid J. 2016; 5 (1): 9—26.Kahaly G. J., Bartalena L., Hegedus L. et al. European Thyroid Association guideline for the management of Graves´ hyperthyroidism. Eur. Thyroid J. 2018; 7 (4): 167—86.Kahaly G. J., Bartalena L., Hegedus L. et al. European Thyroid Association guideline for the management of Graves´ hyperthyroidism. Eur. Thyroid J. 2018; 7 (4): 167—86.Bartalena L., Kahaly G. J., Baldeschi L. et al. EUGOGO. The 2021 European Group on Graves´ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves´ orbitopathy. Eur. J. Endocrinol. 2021; 185 (4): G43— G67. doi: 10.1530/EJE-21-0479.Bartalena L., Kahaly G. J., Baldeschi L. et al. EUGOGO. The 2021 European Group on Graves´ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves´ orbitopathy. Eur. J. Endocrinol. 2021; 185 (4): G43— G67. doi: 10.1530/EJE-21-0479.Burch H. B., Perros P., Bednarczuk T. et al. Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. Eur. Thyroid J. 2022; 11 (6): e220189.Burch H. B., Perros P., Bednarczuk T. et al. Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. Eur. Thyroid J. 2022; 11 (6): e220189.Mourits M. P., Prummel M. F., Wiersinga W. M., Koornneef L. Clinical activity score as a guide in the management of patients with Graves´ ophthalmopathy. Clin. Endocrinol. (Oxf). 1997; 47 (1): 9—14.Mourits M. P., Prummel M. F., Wiersinga W. M., Koornneef L. Clinical activity score as a guide in the management of patients with Graves´ ophthalmopathy. Clin. Endocrinol. (Oxf). 1997; 47 (1): 9—14.Perez-Moreiras J. V., Varela-Agra M., Prada-Sanchez M. C., PradaRamallal G. Steroid-resistant Graves´ orbitopathy treated with tocilizumab in real-world clinical practice: a 9- year single-center experience. J. Clin. Med. 2021; 10 (4):706. doi. org/10.3390/jcm10040706. Perez-Moreiras J. V., Alvarez-Lopez A., Gomez E. C. Treatment of active corticosteroid-resistant graves´ orbitopathy. Ophthalmic Plast. Reconstr. Surg. 2014; 30 (2): 162—7.Perez-Moreiras J. V., Varela-Agra M., Prada-Sanchez M. C., PradaRamallal G. Steroid-resistant Graves´ orbitopathy treated with tocilizumab in real-world clinical practice: a 9- year single-center experience. J. Clin. Med. 2021; 10 (4):706. doi. org/10.3390/jcm10040706. Perez-Moreiras J. V., Alvarez-Lopez A., Gomez E. C. Treatment of active corticosteroid-resistant graves´ orbitopathy. Ophthalmic Plast. Reconstr. Surg. 2014; 30 (2): 162—7.Perez-Moreiras J. V., Gomez-Reino J. J., Maneiro J. R. et al Efficacy tocilizumab in patients with moderate-to-severe corticosteroidresistant graves orbitopathy: A randomized clinical trial. Am. J. Ophthalmol. 2018; 195: 181—90.Perez-Moreiras J. V., Gomez-Reino J. J., Maneiro J. R. et al Efficacy tocilizumab in patients with moderate-to-severe corticosteroidresistant graves orbitopathy: A randomized clinical trial. Am. J. Ophthalmol. 2018; 195: 181—90.Copperman T., Idowu O. O., Kersten R. C., Vagefi M. R. Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery. Ophthalmic Plast. Reconstr. Surg. 2019; 35: e64—e66.Copperman T., Idowu O. O., Kersten R. C., Vagefi M. R. Subcutaneous tocilizumab for thyroid eye disease: simplified dosing and delivery. Ophthalmic Plast. Reconstr. Surg. 2019; 35: e64—e66.Silkiss R. Z., Paap M. K., Roelofs K. A. et al Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab. Can. J. Ophthalmol. 2021; 56: 66—70.Silkiss R. Z., Paap M. K., Roelofs K. A. et al Treatment of corticosteroid-resistant thyroid eye disease with subcutaneous tocilizumab. Can. J. Ophthalmol. 2021; 56: 66—70.Wiersinga W. M., Prummel M. F., Terwee C. B. Effects of Graves´ ophthalmopathy on quality of life. J. Endocrinol. Invest. 2004; 27: 259—64.Wiersinga W. M., Prummel M. F., Terwee C. B. Effects of Graves´ ophthalmopathy on quality of life. J. Endocrinol. Invest. 2004; 27: 259—64.

The authors declare that there are no conflicts of interest present.